



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	J-Lat Tat-GFP Cells (A7)
Catalog Number:	9853
Lot Number:	150245
Release Category:	C
Provided:	1 mL at 4.7×10^6 cells/vial. 92% viability.
Cell Type:	Jurkat - T lymphocyte cell line
Propagation Medium:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM, 0.3 mg/ml).
Freeze Medium:	FBS, 90%; DMSO, 10%.
Growth Characteristics:	No special requirements, split 1:3 at 1×10^6 cells/ml. Cells grow in suspension, usually singly but some clumping has been noted.
Morphology:	Small, spherical cells in suspension. Morphology usually does not vary.
Sterility:	Negative for bacteria, mycoplasma, and fungi.
Description:	These cells are Jurkat cells that bear the integrated retroviral construct LTR-Tat-IRES-GFP.
Special Characteristics:	Jurkat cells were infected with viral particles bearing the retroviral construct LTR-Tat-IRES-GFP. Cells that were GFP negative, but could be stimulated to express GFP were selected. For the other similar cells, please see cat#s 9846-9856.
Recommended Storage:	Liquid nitrogen

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: Dr. Eric Verdin.

References: Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. *EMBO J* **22**:1868-1877, 2003.

Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. *EMBO J* **20**:1726-1738, 2001.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Tat-GFP Cells (clone #) from Dr. Eric Verdin." Also include the references cited above in any publication.

These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated November 09, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.